Keyphrases
Humoral Immunity
44%
T Cell Exhaustion
44%
Spike Receptor Binding Domain
44%
SARS-CoV-2 Spike Protein
44%
Responsive Delivery
44%
Biodegradable Carrier
44%
Insulin Loading
44%
High-tech Business
44%
University Spin-offs
44%
Failed Companies
44%
Lab-to-market
44%
Microfluidic Device
44%
Company Failures
44%
Technology-intensive Sectors
44%
Microfluidics
44%
Glucose-responsive Nanoparticles
44%
Interleukin-12 (IL-12)
44%
Protein Microgels
44%
Interleukin-7 (IL-7)
44%
Lab Culture
44%
Cellular Immunity
44%
Synergize
44%
Polymersomes
44%
Combination Regimen
29%
Checkpoint Inhibitors
29%
Combination Immunotherapy
29%
Protein Nanofibrils
29%
Receptor-binding Domain
25%
Commercialization Strategy
22%
Turnaround Time
22%
Analytical Device
22%
Article Analysis
22%
Consumer Products
22%
Niche Markets
22%
Value Reduction
22%
Reduction-responsive Nanoparticles
22%
Low Volume
22%
Hydrophilization
22%
High-throughput Screening
22%
Veterinary Science
22%
Market Penetration
22%
Medical Sciences
22%
Limited Diffusion
22%
Environmental Science
22%
Strategic Alignment
17%
Writing Center
17%
Porous Polymer Membrane
14%
Inhibitor Resistant
14%
Combination of Therapies
14%
T Cells
14%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
88%
Humoral Immunity
88%
Adoptive Immunity
88%
Spike
75%
Adjuvant
50%
Receptor Binding
48%
T Cell
48%
Toll-Like Receptor
44%
Polymersome
44%
Interleukin 7
44%
Polymerization
44%
Immunotherapy
44%
Vaccine Efficacy
30%
Vaccination Policy
21%
Surface Property
19%
Mouse
15%
Titer
15%
Systemic Inflammation
14%
Cancer Immunotherapy
14%
Intravenous Immunoglobulin
14%
Neutralizing Antibody
12%
Antibody Response
12%
Lymph Node
12%
B Cell
10%
Subunit Vaccine
10%
T-Helper Cell
10%
Cytotoxic T-Cell
10%
Germinal Center
10%
Cytokine
10%
Cell Activation
6%
COVID-19
6%
Virus Particle
6%
Phosphoryl Lipid A
6%
Blood Plasma
6%
Immunocompetent Cell
6%
Pharmacology, Toxicology and Pharmaceutical Science
Nanoparticle
100%
Mouse
74%
Diabetes Mellitus
60%
Alginic Acid
59%
Glucose Oxidase
45%
Toll Like Receptor 7
44%
Polycation
44%
Adjuvant
44%
SARS Coronavirus
44%
Replacement Therapy
44%
High-Throughput Screening
44%
Dextran
41%
Mouse Model
23%
Streptozotocin
20%
Acetal
17%
Biomaterial
14%
Antidiabetic Agent
14%
Hyperglycemia
11%
Hypoglycemia
11%
Gluconic Acid
11%
Cell Viability
11%
Controlled Substance
11%
Subcutaneous Injection
8%
Recombinant Human Insulin
8%
Catalase
8%
Human Insulin
8%
Vaccination Policy
8%
Mannose
8%